TP53 and cancer: RA-FLSs treated with rHAPLN1 were enriched in pathways including protein digestion, S. aureus infection, ECM-receptor interaction, RA, p53 signaling pathway, cholesterol metabolism, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, and pathways for various cancers (Figure 7D).